Sosei (Group)

https://www.sosei.com

Sosei Heptares is a fully integrated biopharmaceutical company focused on bringing life-changing medicines based on world-class science to patients globally. Our vision is to become one of Japan’s global biopharmaceutical champions. Sosei Heptares has a leading development capability and a profitable and growing commercial operation in Japan, which it intends to expand into additional selected markets in the Asia-Pacific region. Sosei Heptares is advancing a broad and deep pipeline of novel medicines created using its world-leading GPCR-targeted StaR® technology and structure-based drug design platform across multiple therapeutic areas, including neurology, immunology, gastroenterology, and inflammatory diseases. In addition, we have leveraged our unique discovery and development capabilities to establish multiple value-generating partnerships with world-leading biopharmaceutical companies, including AbbVie, Genentech (Roche), GSK, Lilly, Neurocrine Biosciences, Novartis, Pfizer, Sanofi and Takeda. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in London and Cambridge, UK. “Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies. For more information, please visit https://soseiheptares.com/ *

	Start	1990-01-01 established
	End	2024-04-01 renamed
	Group	Nxera Pharma (Group)
	Today	Nxera Pharma (Group)
	Successor	Nxera Pharma (Group)
	Industry	pharmaceutical
	Industry 2	BIOTECH
	Person	Tamura, Shinichi (Sosei 1999 CEO + Founder before Genentech Japan CEO)

	Region	Tokyo
	Country	Japan
	City	n. a. Tokyo
		Address record changed: 2023-07-23

Basic data	Employees	n. a.

		* Document for »About Section«: Idorsia Ltd.. (7/20/23). "Press Release: Idorsia Sells Its Asia Pacific (ex-China) Operations – Including Select License Rights to Products – to Sosei Heptares for a Total Consideration of CHF 400 Million". Allschwil.

		Record changed: 2024-09-06